Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Rating Upgraded by Leerink Partnrs

Leerink Partnrs upgraded shares of Ironwood Pharmaceuticals (NASDAQ:IRWD – Free Report) to a hold rating in a report issued on Monday morning, Zacks.com reports. Leerink Partnrs also issued estimates for Ironwood Pharmaceuticals’ Q3 2024 earnings at $0.03 EPS, Q4 2024 earnings at $0.09 EPS, FY2024 earnings at $0.10 EPS, Q1 2025 earnings at $0.03 EPS, […]

Leave a Reply

Your email address will not be published.

Previous post Coherus BioSciences, Inc. (NASDAQ:CHRS) Receives $6.92 Average Target Price from Brokerages
Next post Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Rating Upgraded by StockNews.com